**O0143**

**Immune-endocrine biomarkers associated with mental health: a 9-year longitudinal investigation from the Hertfordshire Ageing Study**

R. Hou

University of Southampton, Department Of Psychiatry, Southampton, United Kingdom
doi: 10.1192/j.eurpsy.2022.327

**Introduction:** Ageing is accompanied by the development of low-grade systemic inflammation which may promote changes in the neural systems predisposing to geriatric depression via the hypothalamic-pituitary-adrenal (HPA) axis.

**Objectives:** The aim of this study was to investigate the longitudinal associations between baseline values and conditional changes in immune-endocrine biomarkers and mental health status in a population-based cohort of older adults.

**Methods:** Data from 347 subjects (200 men, 147 women) who participated in the Hertfordshire Ageing Study at baseline (mean age 67.3 years) and at 9-year follow-up were analysed. Serum samples for analysis of inflammatory and endocrinological measures were collected at baseline and follow-up. At follow-up, depression (Hospital Anxiety and Depression Scale) and mental health (Short Form-36 questionnaire) were assessed. Baseline values and changes in biomarkers in relation to risk of high depression scores and low mental health scores were examined using logistic regression.

**Results:** Lower baseline cortisol was related to greater risk of high depression scores; higher baseline cortisol: Dehydroepiandrosterone Sulphate ratio (men only) and higher baseline CRP (women only) were related to greater risk of poor mental health scores. In addition, greater decline in cortisol was related to increased risk of high depression scores among men. These relationships were robust (p < 0.05) after controlling for sex, age, BMI, smoking, alcohol consumption and number of systems medicated.

**Conclusions:** This study provides further evidence of the role of the HPA and inflammation in older adults with poor mental health. In addition, the findings highlight sex differences where increased inflammation in women and declines in cortisol in men was linked to poorer mental health.

**Disclosure:** No significant relationships.

**O0142**

**Biomarkers in the Cerebrospinal Fluid of Patients with Psychotic Disorders Compared to Healthy Controls: A Systematic Review and Meta-Analysis**

T. Rømer*, R. Jeppesen, R. Christensen and M. Benros

University Hospital Copenhagen, Copenhagen Research Center For Mental Health (core), Hellerup, Denmark

*Corresponding author.
doi: 10.1192/j.eurpsy.2022.328

**Introduction:** Biomarkers in CSF could provide etiological clues and diagnostic tools for psychotic disorders. However, an overview of all CSF findings in individuals with psychotic disorders compared to healthy controls is lacking.

**Objectives:** To analyse CSF findings from individuals with psychotic disorders compared to healthy controls.

**Methods:** PubMed, EMBASE, Cochrane Library, Web of Science, ClinicalTrials.gov, and PsycINFO were searched November 3rd, 2021. Case-control studies including patients with non-affective, psychotic disorder compared to healthy controls measuring at least one biomarker in CSF are included. Standardized Mean Differences (SMD) and random-effects analyses were used.

**Results:** 141 studies, covering 192 biomarkers, were included. 161 biomarkers have not previously been included in meta-analyses. Most markers measured showed no significant differences, including the dopamine metabolites HVA and DOPAC. Patients with psychotic disorders showed increased CSF levels of noradrenaline (SMD, 0.53; 95% CI, 0.15-0.90), MHPG (SMD, 0.30; 95% CI, 0.05-0.55), 5-HIAA (SMD, 0.11; 95% CI, 0.01-0.21), kynurenine (SMD, 1.58; 95% CI, 0.26-2.91), kynurenine (SMD, 1.00; 95% CI, 0.58-1.42), IL-6 (SMD, 0.58; 95% CI, 0.39-0.77), IL-8 (SMD, 0.47; 95% CI, 0.18-0.77), anandamide (SMD, 0.78; 95% CI, 0.53-1.02), albumin ratio (SMD, 0.53; 95% CI, 0.10-0.96), total protein (SMD, 0.31; 95% CI, 0.14-0.48), and glucose (SMD, 0.57; 95% CI, 0.08-1.06). Neurotensin (SMD, -0.67; 95% CI, -0.89 to -0.46) and GABA (SMD, -0.29; 95% CI, -0.50 to -0.09) were decreased.

**Conclusions:** These findings suggest that dysregulation of the immune and adrenergic system and blood-brain barrier dysfunction might play a role in the pathophysiology of psychotic disorders.

**Disclosure:** No significant relationships.

**Keywords:** meta-analysis; PSYCHOTIC DISORDERS; cerebrospinal fluid; biomarkers
**Objectives:** This study examines satisfaction with social connectedness (SSC) as predictor of positive and negative symptoms in people with a psychotic disorder.

**Methods:** Data from the Pharmacotherapy Monitoring and Outcome Survey (PHAMOUS, 2014-2019) was used from patients diagnosed with a psychotic disorder (N=2109). Items about social connectedness of the Manchester short assessment of Quality of Life (ManSA) were used to measure SSC. Linear mixed models were used to estimate the association of SSC with the Positive and Negative Syndrome Scale (PANSS) after one and two years against α=0.01. Analyses were adjusted for symptoms, time since onset, gender and age. Additionally, fluctuation of positive and negative symptom scores over time was estimated.

**Results:** Mean duration of illness was 18.8 years (SD 10.7) with >65% showing only small variation in positive and negative symptoms over a two to five-year time period. After adjustment for covariates, SSC showed to be negatively associated with positive symptoms after one year (β=-0.47, p<0.001, 95% CI = -0.70,-0.25) and two years (β = -0.59, p<0.001, 95% CI = -0.88,-0.30), and for negative symptoms after one year (β = -0.52, p<0.001, 95% CI = -0.77,-0.27). The prediction of negative symptoms was not significant at two years.

**Conclusions:** This research indicates that interventions on SSC might positively impact mental health for people with psychosis. SSC is a small and robust predictor of future levels of positive symptoms. Negative symptoms could be predicted by SSC at one year.

**Disclosure:** No significant relationships.

**Keywords:** social connectedness; PSYCHOTIC DISORDERS; positive symptoms; negative symptoms

**O0144**

**DiscoVR: results of a multicenter RCT on a social cognitive virtual reality training to enhance social cognition in psychosis**

G. Pijnenborg1*, S. Nijman2 and W. Veling3

1GGZ Drenthe, Department Of Psychotic Disorders, Assen, Netherlands; 2GGZ Drenthe, Dept Of Psychotic Disorders, Assen, Netherlands and 3University Medical Center Groningen, Universitair Centrum Psychiatrie, Groningen, Netherlands

*Corresponding author.

doi: 10.1192/eurpsy.2022.330

**Introduction:** Functional deficits, that is, problems in fulfilling appropriate social roles in daily life, are very common in people with a psychotic disorder. In recent years, Virtual Reality (VR) has emerged as a potential tool to improve SCT. Our research group has developed an immersive VR-SCT ('Dynamic Interactive Social Cognition Training in Virtual Reality': 'DiSCoVR').

**Objectives:** To evaluate to effects of a VR-based social cognition training (SCT) for people with a psychotic disorder.

**Methods:** This intervention was compared the an active VR-control condition in a multicenter RCT. Both interventions contained sixteen individual 45-60-minute on-site sessions, administered twice a week. Main study outcomes are social cognition and social functioning in daily life assessed with experience sampling.

**Results:** From baseline to post-treatment (n=72), none of the time*group interactions were significant, indicating an absence of treatment effects. A significant effect of time was observed for the SERS total score (β = 9.84, 95% CI = 3.81-15.87, p = .002), indicating overall improvement in self-esteem.

**Conclusions:** We did not find any significant treatment effects. An effect of time on self-esteem was found at post-treatment, but not follow-up, suggesting a temporary improvement in self-esteem in both groups. One way to interpret these results is that, contrary to other SCT interventions, DiSCoVR does not improve social cognition or social functioning. This could be due to characteristics of the treatment protocol. Another possibility is that, contrary to the premise of VR-SCT, our VR environments inadequately simulated reality. Adapting an established protocol to VR, could further elucidate the merit of VR as a training method.

**Disclosure:** No significant relationships.

**Keywords:** virtual reality; social cognition; Psychosis; Treatment

**OO145**

**Alcohol-induced psychotic disorder: a study of hospitalized patients in Lisbon**

V. Nogueira¹*, I. Pereira¹, M. Moreno² and J. Teixeira³

1Avenida do Brasil, número 53, Servico De Alcoologia E Novas Dependências, Lisboa, Portugal; 2Centro Hospitalar Psiquiátrico de Lisboa, Servico De Alcoologia E Novas Dependências, Lisboa, Portugal and ³Centro Hospitalar Psiquiátrico de Lisboa, Clínica 5, Lisboa, Portugal

*Corresponding author.

doi: 10.1192/eurpsy.2022.331

**Introduction:** While alcohol-induced psychotic disorder (AIPD) is a well-recognised clinical disorder, relativity little is known about aspects such as epidemiology, course and treatment of the condition. Current evidence suggests AIPD can be clinically distinguished from alcohol-withdrawal delirium and schizophrenia. AIPD is associated with high comorbidity with other psychiatric disorders, high re-hospitalization and mortality rate, namely suicidal behaviour.

**Objectives:** The objective of the study was to examine the correlates, clinical features, psychopathology, and short-term response in an inpatient sample with alcohol-induced psychotic disorder, predominant hallucinations (ICD-10 F10.52) admitted to Centro Hospitalar Psiquiátrico de Lisboa.

**Methods:** We collected retrospectively data from all admitted patients to our Alcohol Unit between January 2010 and January 2020 with the diagnosis of AIPD. The exclusion criteria were: presence of preexisting psychotic disorder, delirium, or other substance use disorders. We characterized our sample in Demographic categories, Clinical categories, Treatment and Short-term course.

**Results:** A total of 113 subjects were included in the study. The prevalence of alcoholic hallucinosis was found to be 1.3% of all patients who received inpatient treatment. Most individuals reported auditory hallucinations, that initiated when they